Drug class
The therapeutic drug class "Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib." consists of targeted oncology agents that selectively inhibit the alpha isoform of phosphatidylinositol-3-kinase (PI3Ka), which is encoded by the *PIK3CA* gene. Read more about Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib.
5 drugs in this class 3 manufacturers
The therapeutic drug class "Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib." consists of targeted oncology agents that selectively inhibit the alpha isoform of phosphatidylinositol-3-kinase (PI3Ka), which is encoded by the *PIK3CA* gene.
By selectively blocking this kinase, these medications disrupt the hyperactive intracellular PI3K/Akt/mTOR signaling cascade, thereby suppressing cancer cell proliferation, cellular survival, and tumor progression driven by oncogenic mutations.
Clinically, members of this class—such as alpelisib and inavolisib—are primarily indicated for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (*HR+*/*HER2-*), *PIK3CA*-mutated advanced or metastatic breast cancer, often administered in combination with endocrine therapies.
The therapeutic drug class "Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib." consists of targeted oncology agents that selectively inhibit the alpha isoform of phosphatidylinositol-3-kinase (PI3Kα), which is encoded by the *PIK3CA* gene Clinically, members of this class—such as alpelisib and inavolisib—are primarily indicated for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (*HR+*/*HER2-*), *PIK3CA*-mutated advanced...
The therapeutic drug class "Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib." consists of targeted oncology agents that selectively inhibit the alpha isoform of phosphatidylinositol-3-kinase (PI3Kα), which is encoded by the *PIK3CA* gene By selectively blocking this kinase, these medications disrupt the hyperactive intracellular PI3K/Akt/mTOR signaling cascade, thereby suppressing cancer cell proliferation, cellular survival, and tumor progression driven by oncogenic mutations
The therapeutic drug class "Antineoplastic - Phosphatidylinositol 3-Kinase Alpha Inhib." consists of targeted oncology agents that selectively inhibit the alpha isoform of phosphatidylinositol-3-kinase (PI3Kα), which is encoded by the *PIK3CA* gene
By selectively blocking this kinase, these medications disrupt the hyperactive intracellular PI3K/Akt/mTOR signaling cascade, thereby suppressing cancer cell proliferation, cellular survival, and tumor progression driven by oncogenic mutations
Clinically, members of this class—such as alpelisib and inavolisib—are primarily indicated for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (*HR+*/*HER2-*), *PIK3CA*-mutated advanced or metastatic breast cancer, often administered in combination with endocrine therapies
Clinically, members of this class—such as alpelisib and inavolisib—are primarily indicated for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (*HR+*/*HER2-*), *PIK3CA*-mutated advanced or metastatic breast cancer, often administered in combination with endocrine therapies
Following a drug class requires a free Physicians Office Resource account.
